By Professor David Goldstein

Journal articles

Webber K; Girgis A; Bennett BK; Bonaventura A; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602

Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Moore MJ; Seay TE; Tjulandin S; Ma WW; Saleh MN; Harris M; Reni M; Ramanathan RK; Tabernero J; Hidalgo M; Van Cutsem E; Goldstein D; Wei X; Iglesias JL; Renschler MF, 2013, 'Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)', JOURNAL OF CLINICAL ONCOLOGY, 31, http://dx.doi.org/10.1200/jco.2013.31.4_suppl.lba148

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines', World Journal of Cancer Research, http://dx.doi.org/10.1166/wjcr.2013.1005

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204

Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N, 2013, 'Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer', International Journal of Radiation Oncology Biology Physics, 85, pp. 157 - 162, http://dx.doi.org/10.1016/j.ijrobp.2012.03.003

Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF, 2013, 'Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine', New England Journal of Medicine, 369, pp. 1691 - 1703, http://dx.doi.org/10.1056/NEJMoa1304369

Tan CJ; Yang JL; Crowe P; Goldstein D, 2013, 'Targeted therapy in soft tissue sarcoma-A novel direction in therapeutics', Chinese Clinical Oncology, 2, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.08.01

Reni M; Von Hoff D; Chiorean E; Ervin T; Arena F; Infante J; Bathini V; Clingan P; Kunzmann V; Ramanathan R; Tabernero J; Goldstein D; Ko A; Lu B, 2013, 'CA19-9 Decrease and Kinetics in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer', Annals of Oncology, 24, pp. iv31 - iv31, http://dx.doi.org/10.1093/annonc/mdt202.19

Hammel P; Huguet F; van Laethem J-L; Goldstein D; Glimelius B; Borbath I; Bouché O; Shannon J; André T; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study', Pancreatology, 13, pp. S89 - S89, http://dx.doi.org/10.1016/j.pan.2013.04.312

Huguet F; Hammel P; Goldstein D; Spry N; Van Laethem J-L; Van Houtte P; Glimelius B; Gubanski M; Bonnetain F; Racadot S, 2013, 'Étude de la relation entre le score d’assurance qualité de la radiothérapie, la toxicité et la survie dans l’essai de phase III LAP07 dans le cancer du pancréas localement évolué', Cancer/Radiothérapie, 17, pp. 581 - 582, http://dx.doi.org/10.1016/j.canrad.2013.06.018

Butow PN; Aldridge L; Bell M; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; King M; Duggal-beri P; Goldstein D, 2013, 'Inferior health-related quality of life and psychological well-being in immigrant cancer survivors: A population-based study', European Journal of Cancer, 49, pp. 1948 - 1956, http://dx.doi.org/10.1016/j.ejca.2013.01.011

Tabernero J; Von Hoff D; Moore M; Ervin T; Arena F; Chiorean E; Infante J; Hingorani S; Ganju V; Weekes C; Scheithauer W; Ramanathan R; Goldstein D; Wei X; Romano A, 2013, 'Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors on Survival', Annals of Oncology, 24, pp. iv11 - iv12, http://dx.doi.org/10.1093/annonc/mdt201.1

Butow PN; Bell M; Aldridge L; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; King M; Duggal-beri P; McGrane J; Goldstein D, 2013, 'Unmet needs in immigrant cancer survivors: a cross-sectional population-based study', Supportive Care in Cancer, 21, pp. 2509 - 2520, http://dx.doi.org/10.1007/s00520-013-1819-2

Goldstein D; Bennett BK; Webber K; Lloyd AR, 2012, 'Reply to A. Giacalone et al', Journal of Clinical Oncology, 30, pp. 4175 - 4176, http://dx.doi.org/10.1200/JCO.2012.45.6269

Ngan S; Fisher R; Burmeister B; Mackay J; McLachlan S; Beresford J; McClure B; Goldstein D; Joseph D; Solomon M, 2012, 'Long-term Quality of Life in Patients Treated in TROG 01.04: A Randomized Trial Comparing Short Course and Long Course Preoperative Radiation Therapy for Rectal Cancer', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84, pp. S143 - S144, http://dx.doi.org/10.1016/j.ijrobp.2012.07.371

Butow P; Aldridge L; Bell M; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; Goldstein D; King MT, 2012, 'Inferior quality of life and psychological well-being in immigrant cancer survivors', QUALITY OF LIFE RESEARCH, 21, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209358900132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fawcett J; Sjoquist KM; Padbury R; Christophi C; Tebbutt NC; Pilgrim CHC; Gebski V; Wong N; Aiken C; Goldstein D, 2012, 'ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.', Journal of Clinical Oncology, 30, pp. TPS3643 - TPS3643, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps3643

Butow PN; Aldridge L; Bell M; Sze M; Eisenbruch M; King M; Jefford M; Schofield P; Duggal-Beri P; Goldstein D, 2012, 'Cancer survivorship outcomes in immigrants.', Journal of Clinical Oncology, 30, pp. 6111 - 6111, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6111

Goldstein D; Sze M; Bell M; King M; Jefford M; Eisenbruch M; Girgis A; Vaccaro L; Butow PN, 2012, 'Disparities in quality-of-life outcomes in immigrant cancer patients.', Journal of Clinical Oncology, 30, pp. e16507 - e16507, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16507

Chua YJ; Karapetis CS; Underhill C; Nott LM; Goldstein D; Cronk MF; Gebski V; Wong N; Sjoquist KM; Biankin AV, 2012, 'PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.', Journal of Clinical Oncology, 30, pp. TPS4137 - TPS4137, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4137

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044

Kiely BE; Martin AJ; Tattersall MHN; Nowak AK; Goldstein D; Wilcken N; Wyld D; Beale PJ; Jefford M; Glasgow AL; Abdi EA; Glare PA; Stockler MR, 2012, 'Usefulness of medical oncologists’ estimates of survival time in people with advanced cancer.', Journal of Clinical Oncology, 30, pp. 9087 - 9087, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9087

Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I; Romedi M; Ferrandini S; Rondinon M; Pittman K; Goldstein D; Shapiro J; Troon S; Yip D; Mainwaring P; Zigeuner R; Loidl W; Greil RF; Schmidinger M; De Grève J; Rottey S; Vermorken J; Gil T; Gennigens C; Roumeguere T; Barrios C; Mathias C; Assi H; Hotte S; Karakiewicz P; Knox J; Spadafora S; Wood L; Zalewski P; Mackensie M; Bjarnason G; Lalancette A; Chan A; Higgins B; North S; Soulieres D; Asselah J; Sperlich C; Miller W; Yadav S; El-Maraghi R; Godoy J; Prausová J; Katolicka J; Petruzelka L; Kiss I; Lapela M; Miller K; Bergmann L; Beck J; Jäger E; Kindler M; Overkamp F; Wirth M; Hölzer W; Gschwend J; Stenzl A; Gauler T; Niederwieser D; Marschner N; Lück A; Tessen H; Eichelberg C; Steiner T; Goebell P; Kettner E; Bakhshandeh-Bath A; Wilhelm M; Schmitz S; Jacob A; Bierer S; Kube U; Staehler M; Engel E; Frambach M; Schellenberger U; Albers P; Simon J; Gleissler M; Klotz T; Repp R, 2012, 'An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy', European Journal of Cancer, 48, pp. 324 - 332, http://dx.doi.org/10.1016/j.ejca.2011.06.054

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Mark Jeffrey G; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; John Simes R, 2012, 'Erratum: Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis (European Journal of Cancer (2011) 47:12 (1826-1836))', European Journal of Cancer, 48, pp. 407, http://dx.doi.org/10.1016/j.ejca.2011.12.001

Butow P; Lobb EA; Jefford M; Goldstein D; Eisenbruch M; Girgis A; King MT; Sze M; Aldridge L; Schofield P, 2012, 'A bridge between cultures: Interpreters' perspectives of consultations with migrant oncology patients', Supportive Care in Cancer, 20, pp. 235 - 244, http://dx.doi.org/10.1007/s00520-010-1046-z

Dumont AG; Rink L; Godwin AK; Miettinen M; Joensuu H; Strosberg JR; Gronchi A; Corless CL; Goldstein D; Rubin BP; Maki RG; Lazar AJ; Lev D; Trent JC; von Mehren M, 2012, 'A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.', Annals of Oncology, 23, pp. 1335 - 1340, http://dx.doi.org/10.1093/annonc/mdr442

Goldstein D; Bennett BK; Webber K; Boyle F; De Souza P; Wilcken NRC; Scott E; Toppler R; Murie P; O''Malley L; Mccourt J; Friedlander M; Hickie IB; Lloyd AR, 2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148

Demetri GD; Garrett C; Sch offski P; Shah M; Verweij J; Leyvraz S; Hurwitz HI; Lopez Pousa A; Le Cesne A; Goldstein D; Paz-Ares L; Blay J; McArthur G; Xu Q; Huang X; Harmon CS; Tassell V; Cohen DP; Casali P, 2012, 'Complete Longitudinal Analyses of the Randomized,Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure', Clinical Cancer Research, 18, pp. 3170 - 3179

Minkovich L; Mccluskey S; Djaiani G; Goldstein D, 2012, 'High prevalence of significant hypophosphatemia in patient undergoing reconstructive surgery for head and neck cancers', European Journal of Anaesthesiology, 29, pp. 185 - 185, http://dx.doi.org/10.1097/00003643-201206001-00614

Bennett BK; Park SB; Lin CS-Y; Friedlander M; Kiernan MC; Goldstein D, 2012, 'Impact of Oxaliplatin-induced Neuropathy: A Patient Perspective', Supportive Care in Cancer, 20, pp. 2959 - 2967, http://dx.doi.org/10.1007/s00520-012-1428-5

Cameron BA; Bennett B; Li H; Boyle F; deSouza P; Wilcken N; Friedlander M; Goldstein D; Lloyd AR, 2012, 'Post-cancer fatigue is not associated with immune activation or altered cytokine production', Annals of Oncology, 23, pp. 2890 - 2895, http://dx.doi.org/10.1093/annonc/mds108

Mitchison D; Butow PN; Sze M; Aldridge L; Hui R; Vardy JL; Eisenbruch M; Iedema R; Goldstein D, 2012, 'Prognostic Communication Preferences of Migrant Patients and their Relatives', Psycho-oncology, 21, pp. 496 - 504, http://dx.doi.org/10.1002/pon.1923

Butow PN; Philips F; Schweder J; White K; Underhill C; Goldstein D, 2012, 'Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review', Supportive Care in Cancer, 20, pp. 1 - 22

Ngan SY; Burmeister B; Fisher R; Solomon M; Goldstein D; Joseph D; Ackland S; Schache D; McClure B; McLachlan S; McKendrick J; Leong T; Hartopeanu C; Zalcberg J; Mackay J, 2012, 'Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30, pp. 3827 - 3833

Wang X; Crowe PJ; Goldstein D; Yang JL, 2012, 'STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers', International Journal of Oncology, 41, pp. 1181 - 1191, http://dx.doi.org/10.3892/ijo.2012.1568

Goldstein D; Spry N; Cummins MM; Brown C; Van Hazel GA; Carroll SL; Selva Nayagam S; Borg M; Ackland S; Wratten C; Shapiro J; Porter L; Hruby G; Horvath LG; Bydder S; Underhill C; Harvey JE; Gebski V, 2012, 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106, pp. 61 - 69, http://dx.doi.org/10.1038/bjc.2011.526

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge LJ; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: A systematic review and meta-analysis', The Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470-2045(11)70212-1

Peng J; Shi D; Goodman KA; Goldstein D; Xiao C; Guan Z; Cai S, 2011, 'Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29', Radiation Oncology, 6, pp. 93, http://dx.doi.org/10.1186/1748-717X-6-93

Butow PN; Goldstein D; Bell ML; Sze M; Aldridge LJ; Abdo S; Tanious M; Dong S; Iedema R; Vardy J; Ashgari R; Hui R; Eisenbruch M, 2011, 'Interpretation in consultations with immigrant patients with cancer: How accurate is it?', Journal of Clinical Oncology, 29, pp. 2801 - 2807, http://dx.doi.org/10.1200/JCO.2010.34.3335

Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533

Hammel P; Huguet F; Van Laethem J; Goldstein D; Glimelius B; Moore MJ; Chibaudel B; Bonnetain F; Louvet C, 2011, 'Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib—LAP 07 study.', Journal of Clinical Oncology, 29, pp. e14619 - e14619, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e14619

Goldstein D; Lee C; Tracey E; Cook-Yarborough C; Lord S, 2011, 'Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib.', J Clin Oncol, 29, pp. 10060, http://www.ncbi.nlm.nih.gov/pubmed/28021288

Arun SJ; Xu Z; Fiala-Beer E; Phillips P; Goldstein D; Biankin A; Pirola R; Wilson JS; Apte MV, 2011, 'Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-395

Yang JL; DasGupta R; Hopkins A; Luk F; Goldstein D; Crowe P, 2011, 'Significance of IGF-1R and Its signaling pathways in human sarcoma', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-4416

Goldstein D; Gainford MC; Brown C; Tebbutt N; Ackland SP; Van Hazel G; Jefford M; Abdi E; Selva-Nayagam S; Gebski V; Miller D; Shannon J, 2011, 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67, pp. 519 - 525, http://dx.doi.org/10.1007/s00280-010-1351-8

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ, 2011, 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis', European Journal of Cancer, 47, pp. 1826 - 1836, http://dx.doi.org/10.1016/j.ejca.2011.04.024

Zhi J; Major P; Chen E; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D, 2011, 'A multi-centre, randomised, open-lable study to assess the steady state paramacokinetics of Bevacizumab given with either Xeloda or FOLFOX-4 in patient with metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1199 - 1206

Sjoquist KM; Goldstein D; Bester L; Bester L, 2011, 'A serious complication of selected internal radiation therapy: case report and literature review', Oncologist, 15, pp. 830 - 835

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Goldstein D; Gainford M; Brown C; Tebbutt N; Ackland S; Van Hazel GA; Jefford M; Abdi E; Gebski V; Miller D; Shannon JF, 2011, 'Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 16, pp. 519 - 519

Back to profile page